NCT06924320View on ClinicalTrials.gov

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

PHASE1RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

January 31, 2026

Conditions
Obesity and Obesity-related Medical Conditions
Interventions
DRUG

MET233 and MET097

For subcutaneous administration

DRUG

Placebo

Sterile 0.9% (w/v) saline for subcutaneous administration.

DRUG

MET233

For subcutaneous administration

Trial Locations (1)

90630

RECRUITING

Research Site MET233/097 24-101-001, Cypress

Sponsors

Lead Sponsor

Metsera
All Listed Sponsors
lead

Metsera

INDUSTRY